Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Fibroblast Growth Factor Receptors and Ligands in Context of Bevacizumab Response in Ovarian Carcinoma: An Exploratory Analysis of AGO-OVAR11/ICON-7.
Lab Invest
; 104(4): 100321, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38154497
3.
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Lancet
; 402(10411): 1423-1433, 2023 10 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37633306
4.
Health-related quality of life with sacituzumab govitecan in HR+/HER2- metastatic breast cancer in the phase III TROPiCS-02 trial.
Oncologist
; 2024 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38748596
5.
Systematic Analysis of Homologous Recombination Deficiency Testing in Ovarian Cancer-Development of Recommendations for Optimal Assay Performance.
Mod Pathol
; 37(4): 100445, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38341130
6.
A plain language summary of the TROPiCS-02 study in patients with breast cancer (HR-positive/HER2-negative).
Future Oncol
; 20(11): 635-651, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38270051
7.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Oncologist
; 28(1): 23-32, 2023 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239405
8.
Quality of therapy in early ovarian cancer: results of the quality assurance program of the AGO Study Group.
Int J Gynecol Cancer
; 33(7): 1083-1089, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37001891
9.
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
Int J Mol Sci
; 24(3)2023 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36769215
10.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
N Engl J Med
; 381(25): 2416-2428, 2019 12 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-31851799
11.
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
BMC Cancer
; 22(1): 1040, 2022 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36195836
12.
Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon.
Future Oncol
; 18(28): 3199-3215, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36069628
13.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
14.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
15.
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Lancet Oncol
; 22(8): 1151-1161, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34252375
16.
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
BMC Cancer
; 21(1): 920, 2021 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34391399
17.
Alpelisib in the treatment of metastatic HR+ breast cancer with PIK3CA mutations.
Future Oncol
; 17(1): 13-36, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32964734
18.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34593565
19.
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Lancet Oncol
; 21(5): 699-709, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32305099
20.
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer.
Future Oncol
; 16(12): 705-715, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32223649